MBRX News and Press, Moleculin Biotech Inc. From 01/18/22

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma - Review of preliminary interim data continues to demonstrate the absence of cardiotoxicity for Annamycin, repr...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...

Moleculin to Present at the H.C. Wainwright BioConnect Conference PR Newswire HOUSTON , Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of...

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases - Preliminary data currently demonstrate 50% of patients in first two cohorts experienced clinical activity, defined as st...

Moleculin Biotech (NASDAQ:MBRX) perks up 5.3% premarket after FDA allowed its Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 dose escalation...

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme New US IND enables parallel development of WP1122 as a cancer therapy PR Newswire HOUSTON , Dec. 1, 2021 /PRNewswire/ -- Moleculin Bi...

Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event - Live moderated video webcast discussion among members of management and Thought Leader Sant P. Chawla, MD on Thursday, November 18th at 11:00 AM ET - PR Newswire HOUSTON , Nov. 12, 202...

Moleculin Biotech (NASDAQ:MBRX): Q3 GAAP EPS of -$0.15 beats by $0.05. Cash and cash equivalents of $75.18M. Press Release For further details see: Moleculin Biotech EPS beats by $0.05

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update - Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 - - Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...